Quarterly UpdatesJul 29, 2026, 04:09 PM
Inovio estimates Q2 2026 cash and equivalents at $36.7M
AI Summary
Inovio Pharmaceuticals, Inc. provided an update on its preliminary financial condition for the quarter ended June 30, 2026. The company estimates its cash and cash equivalents were approximately $36.7 million as of that date. This unaudited information is subject to the completion of the company's financial closing procedures.
Key Highlights
- Estimated cash and cash equivalents were approximately $36.7 million.
- Financial data is as of June 30, 2026.
- Information is preliminary, unaudited, and subject to financial closing procedures.
Price Impact
More from INO